 A recent study of the nootropic effects of LSD, published in the scientific journal Experimental Neurology, is validating for BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF and its LSD analog BETR-001, according to the companys CEO. The study, Nootropic effects of LSD: Behavioral, molecular and computational evidence, provided new evidence that LSD has nootropic improving cognitive function effects, which are believed to be driven by neuroplasticity promotion. 